TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19068785

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (alendronate, risedronate) and raloxifene (selective estrogen receptor modulator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy based on fracture risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early treatment for glucocorticoid- and diabetes mellitus-induced osteoporosis
Number of subjects: 0
Study: 16567393

Group type: COMPARATOR
Intervention: Cord clamping within the first 15 seconds (group 1)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Cord clamping at 1 minute (group 2)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Cord clamping at 3 minutes (group 3)
Number of subjects: 276
Study: 12606904

Group type: EXPERIMENTAL
Intervention: Approximate entropy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bispectral index
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spectral edge frequency 95 (SEF95)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of drug concentrations (propofol and remifentanil)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tolerance of airway manipulation
Number of subjects: 20
Study: 10575642

Group type: EXPERIMENTAL
Intervention: Iontophoresis using nonbuffered electrode at 80 mA/min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Iontophoresis using buffered electrodes (preloaded immobile resins or simple phosphates)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Iontophoresis using nonbuffered electrode at 20 and 40 mA/min
Number of subjects: 60
Study: 8708127

Group type: EXPERIMENTAL
Intervention: Chloral hydrate 50 mg/kg with hydroxyzine 25 mg (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 0.5 mg/kg with acetaminophen elixir 10 mg/kg (Group 2)
Number of subjects: 0
Study: 1764770

Group type: EXPERIMENTAL
Intervention: Ionic lens (Bufilcon A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non-ionic lens (Tetrafilcon A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control HEMA lens
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Surfactant cleaning
Number of subjects: 10
Study: 6761238

Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31549861

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (n = 46)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (n = 45)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall participants (experimental + control = 91)
Number of subjects: 91
Study: 31481017

Group type: EXPERIMENTAL
Intervention: BATHE technique used by GPs during consultations
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: BATHE technique
Number of subjects: 577
Study: 28121797

Group type: EXPERIMENTAL
Intervention: Immediate feeding (IF) with CHO + PRO (1.5 g·kg BM dextrose and 0.5 g·kg BM whey) ingested immediately postexercise.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Delayed feeding (DF) with PLA ingested immediately postexercise and CHO + PRO solution 2 h postexercise.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA) solution ingested immediately and 2 h postexercise.
Number of subjects: 10
Study: 26936134

Group type: EXPERIMENTAL
Intervention: Low-fat/low-salt (0.02% fat, 0.06% NaCl)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-fat/high-salt (0.5% NaCl)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-fat/low-salt (34% fat)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-fat/high-salt
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low salt
Number of subjects: 48
Study: 24979556

Group type: EXPERIMENTAL
Intervention: Probiotics (combination)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 22869486

Group type: EXPERIMENTAL
Intervention: Midazolam with remifentanil (group MR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam alone (group M)
Number of subjects: 60
Study: 19233930

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (3M Espe)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Futurabond NR (Voco)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Transbond Plus (3M Unitek)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional acid etching system Etch-Rite (Pulpdent Corp.)
Number of subjects: 96
Study: 17768467

Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide 1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Suxamethonium 1 mg/kg
Number of subjects: 60
Study: 15673635

Group type: EXPERIMENTAL
Intervention: Stress-writing group (n = 41)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Positive-writing group (n = 37)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (neutral experiences, n = 36)
Number of subjects: 137
Study: 11902852

Group type: EXPERIMENTAL
Intervention: 5 a Day Achievement Badge program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (received the program later)
Number of subjects: 0
Study: 9598008

Group type: EXPERIMENTAL
Intervention: Liposomal lidocaine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Liposomal lidocaine (5%)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lidocaine in nonliposomal vehicles
Number of subjects: 19

Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 19
Study: 7938127

Group type: COMPARATOR
Intervention: Marihuana (0.004% placebo)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Marihuana (1.24% THC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Marihuana (2.64% THC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Marihuana pretreatment
Number of subjects: 5
Study: 3220095

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adinazolam plus Cimetidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31764782

Group type: EXPERIMENTAL
Intervention: Yiqi Huayu Jiedu decoction (YHJD) combined with chemotherapy
Number of subjects: 489

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 489
Study: 28107372

Group type: EXPERIMENTAL
Intervention: Podiatry intervention including foot and ankle exercises, foot orthoses, new footwear if required, and a falls prevention leaflet
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Podiatry intervention
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1010
Study: 25888414

Group type: EXPERIMENTAL
Intervention: beta‐guanidinopropionic acid 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: creatine 5 gram
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 24499111

Group type: EXPERIMENTAL
Intervention: Running suture closure
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Onlay mesh closure
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Sublay mesh closure
Number of subjects: 460
Study: 21145085

Group type: EXPERIMENTAL
Intervention: Containment elastic orthosis and manual lymphatic drainage
Number of subjects: 48

Group type: COMPARATOR
Intervention: Postural measures
Number of subjects: 48
Study: 19393844

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 331

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 331
Study: 17263761

Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14970817

Group type: EXPERIMENTAL
Intervention: L5 spinous hook adjustment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower sacroiliac adjustment
Number of subjects: 30
Study: 11761821

Group type: EXPERIMENTAL
Intervention: Triamcinolone (400 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Formoterol (24 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 9418312

Group type: EXPERIMENTAL
Intervention: Interpleural block with 0.4 ml/kg bupivacaine, 0.5% before induction of general anesthesia, followed by continuous administration of bupivacaine 0.25%, 0.125 ml/kg/hr.
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anesthesia (control group).
Number of subjects: 30
Study: 8357472

Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Cetirizine (10 mg)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 193

Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 193
Study: 3306380

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg nightly for 7 to 10 nights (abrupt-withdrawal group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tapered-dosage of triazolam: 0.5 mg for 7 nights, 0.25 mg for 2 nights, 0.125 mg for 2 nights (tapered-dosage group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (initial treatment for both groups)
Number of subjects: 60
Study: 2508417

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinylestradiol and gestodene
Number of subjects: 19

Group type: COMPARATOR
Intervention: Triphasic oral contraceptive containing ethinylestradiol and levonorgestrel
Number of subjects: 19
Study: 31562800

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus veliparib followed by veliparib maintenance (veliparib throughout)
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus veliparib followed by placebo maintenance (veliparib combination only)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Chemotherapy plus placebo followed by placebo maintenance (control)
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus veliparib
Number of subjects: 1140
Study: 28526486

Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patches (50 μg hour−1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patches (75 μg hour−1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patches (100 μg hour−1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patches (35 μg hour−1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patches (70 μg hour−1)
Number of subjects: 24
Study: 25835218

Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simulation plus workshop
Number of subjects: 40
Study: 23934680

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low sodium diet-fructose
Number of subjects: 36
Study: 21272992

Group type: EXPERIMENTAL
Intervention: Intravesical administration of hyaluronic acid (HA) and chondroitin sulphate (CS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 19860245

Group type: EXPERIMENTAL
Intervention: BONFILS Retromolar Intubation Fiberscope (B-scope)
Number of subjects: 50

Group type: COMPARATOR
Intervention: StyletScope (S-scope)
Number of subjects: 50
Study: 16499643

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg/day per nostril
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15639693

Group type: EXPERIMENTAL
Intervention: Buprenorphine TES 35 microg/h
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 11518093

Group type: EXPERIMENTAL
Intervention: 15-mg nicotine patch (16-hr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 9140155

Group type: EXPERIMENTAL
Intervention: Jejunoileostomy
Number of subjects: 60
Study: 8424910

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 3115389

Group type: EXPERIMENTAL
Intervention: Stable strontium absorption test with standard breakfast
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Stable strontium absorption test
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Stable strontium absorption test with food
Number of subjects: 72
Study: 29953026

Group type: EXPERIMENTAL
Intervention: Active laser therapy (wavelength: 780 nm; fluence: 134 J/cm; power: 50 mW; irradiance: 1.675 W/cm; exposure time: 80 seconds per point) on 3 points of the masseter and 1 point on the anterior temporal muscles on each side
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sham laser (placebo effect)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 78
Study: 26749451

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (0.25 μg daily for six months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 28
Study: 24509504

Group type: EXPERIMENTAL
Intervention: Socio-ecological intervention promoting physical activity and limiting sedentary behavior
Number of subjects: 732
Study: 23422606

Group type: COMPARATOR
Intervention: Preparation of 2/3 (10.6 mm) of the total root length (G1 - control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Preparation of 1/2 (8 mm) of the total root length (G2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Preparation of 1/3 (5.3 mm) of the total root length (G3)
Number of subjects: 36
Study: 20177860

Group type: EXPERIMENTAL
Intervention: Standardized 200 ml of clear carbohydrate‐enriched drink orally 2 hours before surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: No preoperative feeding (control group)
Number of subjects: 110
Study: 17233286

Group type: EXPERIMENTAL
Intervention: High-intensity signal changes on T2-weighted MR imaging
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Low-intensity signal changes on T1-weighted MR imaging
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: T2-weighted MR imaging
Number of subjects: 67
Study: 16614691

Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (LC) 250 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Naproxen sodium (NS) 550 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (LC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Naproxen sodium (NS)
Number of subjects: 70
Study: 12638395

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg single dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg multiple doses (once daily for 10 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg with high-fat meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 36
Study: 10071726

Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7497662

Group type: EXPERIMENTAL
Intervention: Patella resurfaced
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not resurfaced
Number of subjects: 100
Study: 1791772

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (walking on a treadmill 3 times per week for 20 min at 70% of maximum heart rate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 7112816

Group type: EXPERIMENTAL
Intervention: Catheters changed monthly as well as for infection and/or obstruction
Number of subjects: 17

Group type: COMPARATOR
Intervention: Catheters changed only for infection and/or obstruction
Number of subjects: 17
Study: 30515573

Group type: EXPERIMENTAL
Intervention: Telephone-based reminiscence therapy (TBR)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Telephone support (TS)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 135
Study: 28742260

Group type: EXPERIMENTAL
Intervention: Optimal individualized treatment rule using preference elicitation questionnaire and item response theory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 0
Study: 26733563

Group type: EXPERIMENTAL
Intervention: Vitamin K3 acupuncture point injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline acupuncture point injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vitamin K3 deep muscle injection
Number of subjects: 80
Study: 24969551

Group type: EXPERIMENTAL
Intervention: High monounsaturated fat hypocaloric diet (diet M)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat hypocaloric diet (diet P)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat hypocaloric diet (diet P) in wild genotype
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Both diets in both genotypes
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 391
Study: 22431426

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study: 19158211

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid daily for 30 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.1 mg folic acid daily for 30 weeks
Number of subjects: 40
Study: 17194818

Group type: EXPERIMENTAL
Intervention: Donepezil for six months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (FTD patients not receiving donepezil)
Number of subjects: 12
Study: 15101069

Group type: EXPERIMENTAL
Intervention: CD-ROM cognitive-behavioral self-help treatment (8 sessions)
Number of subjects: 60
Study: 12237988

Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nurse interaction (Control)
Number of subjects: 41
Study: 9809892

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 4312

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4312
Study: 8592249

Group type: EXPERIMENTAL
Intervention: Imidapril hydrochloride (5 mg once a day, increased to 10 mg if necessary)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Enalapril maleate (5 mg once a day, increased to 10 mg if necessary)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Imidapril hydrochloride
Number of subjects: 231

Group type: COMPARATOR
Intervention: Enalapril maleate
Number of subjects: 231
Study: 2650524

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 1000
Study: 608009

Group type: EXPERIMENTAL
Intervention: Conservative procedure (mammary resection plus axillary dissection plus radiotherapy)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 331
Study: 31239119

Group type: EXPERIMENTAL
Intervention: Resistance training (15 weeks, 3 times per week, 8 exercises, 8-12 repetitions, individualized loads)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Unchanged physical activity (control group)
Number of subjects: 65
Study: 28320991

Group type: EXPERIMENTAL
Intervention: Risk score model for contrast-induced nephropathy (CIN) based on age > 75 years, creatinine clearance (CrCl) < 60 mL/minute, and congestive heart failure (CHF)
Number of subjects: 1286

Group type: COMPARATOR
Intervention: CIN group
Number of subjects: 1286
Study: 26082614

Group type: EXPERIMENTAL
Intervention: LMV + ADV
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: LdT + ADV
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: ETV + ADV
Number of subjects: 252

Group type: COMPARATOR
Intervention: LMV + ADV, LdT + ADV, ETV + ADV
Number of subjects: 252
Study: 23421487

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure at 100 μg/m³ PM₁₀ for 2 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Filtered air exposure for 2 hours
Number of subjects: 14
Study: 22384543

Group type: EXPERIMENTAL
Intervention: SNMRM + TAI
Number of subjects: 62

Group type: COMPARATOR
Intervention: TAI
Number of subjects: 62
Study: 19332035

Group type: EXPERIMENTAL
Intervention: Various pharmacological agents including antidepressants, anti-adrenergic agents, anticonvulsants, benzodiazepines, atypical antipsychotics, and novel agents
Number of subjects: 0
Study: 16452647

Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 238
Study: 15356820

Group type: EXPERIMENTAL
Intervention: nelfinavir-indinavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: indinavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: efavirenz-indinavir
Number of subjects: 0
Study: 11696664

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9456189

Group type: EXPERIMENTAL
Intervention: Epirubicin 130 mg/m2 every 3 weeks until disease progression or cumulative dose of 1000 mg/m2 or heart failure occurred
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Epirubicin treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combined criteria: age >=50 years, baseline LVEF <=0.60, decrease in LVEF to 0.50
Number of subjects: 67
Study: 7856686

Group type: EXPERIMENTAL
Intervention: One subdermal estradiol implant
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Three subdermal estradiol implants
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (one and three implants)
Number of subjects: 36
Study: 2159054

Group type: COMPARATOR
Intervention: Intravenous vindesine (V) 3 mg/m2 every 2 weeks
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: V 3 mg/m2 weekly for 5 weeks plus mitomycin (VM) 20 mg/m2 day 1 and then 15 mg/m2 every 6 weeks
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: V at the more intensive dose rate plus cisplatin (VC) 120 mg/m2 with forced diuresis on days 1 and 29 and then every 6 weeks
Number of subjects: 435
Study: 7419959

Group type: EXPERIMENTAL
Intervention: CCK (0.066, 0.125, 0.25, and 0.5 CHR U/kg/hr)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CCK-OP (40 ng/kg/hr) plus secretin (0.25 U/kg/hr)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CCK-OP (20, 40, 80, and 160 ng/kg/hr)
Number of subjects: 6
Study: 31095724

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Direct radiofrequency ablation (dRFA)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Indirect radiofrequency ablation (iRFA)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: All treatments (EVLA, dRFA, iRFA)
Number of subjects: 450
Study: 28131050

Group type: EXPERIMENTAL
Intervention: Ergometer-cycling with strict coach-supervision (STRICT, N=3; n=35)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ergometer-cycling with autonomy-supportive minimal contact coach-supervision (AUT, N=3; n=36)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Both ergometer-cycling programs (STRICT and AUT)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High-adherers (adherence≥80%)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control condition (CON, N=2; n=24)
Number of subjects: 95